• Duman, R. S., Heninger, G. R., and Nestler, E. J. (1994) Molecular psychiatry, adaptations of receptor-coupled signal transduction pathways underlying stress-and drug-induced neural plasticity. (springer.com)
  • Both of these pathways are regulated by dopamine. (jneurosci.org)
  • Indeed, in mouse studies, the Borrelli team discovered that removing D2 receptors in nerve cells (cholinergic interneurons) did not result in catalepsy in the mice upon antipsychotic treatment. (eurekalert.org)
  • D2 dopamine receptors are targeted by antipsychotic agents to regulate behavior. (sciencemag.org)
  • Overall, this review indicates that different aspects of the addiction phenotype are critically influenced by dopaminergic receptors and that variants of those genes seem to influence some addiction phenotypes in humans. (nih.gov)
  • Turning the theory of how the human brain perceives time on its head, a novel analysis in mice reveals that dopamine neuron activity plays a key role in judgment of time, slowing down the internal clock. (brightsurf.com)
  • Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1. (nih.gov)
  • These data demonstrate pronounced supersensitivity of postsynaptic D2 dopamine receptors in the striatum of TAAR1-KO mice and indicate that a close interaction of TAAR1 and D2 dopamine receptors at the level of postsynaptic structures has important functional consequences. (nih.gov)
  • We will summarize the distribution of these receptors in the brain, the preclinical experiments carried out with pharmacological and transgenic approaches and the genetic studies carried out linking genetic variants of these receptors to drug addiction phenotypes. (nih.gov)
  • Limbird, L. (1988) Receptors linked to inhibition of adenylate cyclase: additional signalling mechanisms. (springer.com)
  • In the isolated proximal tubules obtained from untreated lean rats, dopamine caused concentration-dependent inhibition of the Na,K-ATPase activity, but this inhibitory effect was absent in untreated obese rats. (ahajournals.org)
  • By mutating these arginine residues, we further showed that their methylation enhanced the D2 receptor-mediated inhibition of cyclic adenosine monophosphate (cAMP) signaling in cultured human embryonic kidney (HEK) 293T cells. (sciencemag.org)
  • D2 receptor signaling may mediate protein kinase B, arrestin beta 2, and GSK-3 activity, and inhibition of these proteins results in stunting of the hyperlocomotion in amphetamine treated rats. (wikipedia.org)
  • The ligand 3-N-[11C]methylspiperone, which preferentially binds to dopamine receptors in vivo, was used to image the receptors by positron emission tomography scanning in baboons and in humans. (sciencemag.org)
  • The decrease in phospho-AKT levels, suggesting an increase in D2 dopamine receptor activity in basal conditions, was associated with an increase of AKT/PP2A complex, as revealed by co-immunoprecipitation experiments. (nih.gov)
  • This study not only shows that methylation modulates GPCR signaling but also suggests that this modification may be important for clinically relevant targets like the D2 receptor. (sciencemag.org)
  • Because dopamine receptors can regulate and interact with each other, we studied the interaction of D 1 and D 3 receptors in immortalized RPT cells and mesenteric arteries from Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHRs), and in human coronary artery smooth muscle cells (CASMCs). (ahajournals.org)
  • 1,2 There is increasing evidence for a direct interaction between D 1 -like and D 2 -like receptors in the kidney. (ahajournals.org)
  • 10 There are no studies on the interaction between D 5 and D 3 receptors, but an interaction between D 1 and D 3 receptors has been reported. (ahajournals.org)
  • Finally, we found that the locomotor activation induced by the D2 dopamine receptor agonist quinpirole, but not by the full D1 dopamine receptor agonist SKF-82958, was increased in TAAR1-KO mice. (nih.gov)
  • Four dopamine agonists are now Federal Drug Administration (FDA) approved and available for use in the United States to treat PD: Mirapex® (pramipexole), Requip® (ropinirole), Neupro® (rotigotine) and Apokyn® (apomorphine). (apdaparkinson.org)